The study team found that using MP MRI could reduce the number of people who would need a TRUS biopsy to diagnose if they had prostate cancer.
This study was open for people to join between March 2013 and June 2016. These results were published in January 2017.
About this study
Everyone who joined the study had a MP MRI scan followed by the combined biopsy procedure (TMP biopsy and a TRUS guided biopsy).
The researchers used the TMP biopsy
because it took samples from the entire prostate gland. This made it the most accurate test and they used it find out how many people had prostate cancer.
In this study researchers were looking at clinically significant prostate cancers. A clinically significant cancer means a Gleason score
of greater than or equal to 4+3 or was at least 6mm in length.
723 people agreed to join the study. Of these 576 had the MP MRI scan and the combined biopsy procedure.
The TMP biopsy showed that of these 576 people, 408 (71%) had cancer. Of these 408 people, 230 (41%) had a clinically significant cancer.
The researchers wanted to know how many times the MP MRI scan and the TRUS guided biopsy was able to correctly identify clinically significant cancers. They found it was:
- 93 out of every 100 times (93%) for the MP MRI scan
- 48 out of every 100 times (48%) for the TRUS guided biopsy
They also looked at how many times the 2 tests were able to correctly identify there was no cancer. They found it was:
- 89 out of every 100 times (89%) for the MP MRI scan
- 74 out of every 100 times (74%) for the TRUS guided biopsy
The team then considered proposed situations where the MP MRI scan was used first to find out if a TRUS guided biopsy might be needed. They said that doing the MP MRI scan first could mean that for 27 out of every 100 times (27%) the TRUS guided biopsy mightn’t be necessary.
They said that if MP MRI scan was used first to find out if a TRUS guided biopsy was needed more clinically significant cancers could be found. And this could be as high as 18 more out of every 100 times (18%).
The team are still analysing the cost effectiveness of the PROMIS study.
The team concluded that the number of clinically significant prostate cancers found could be increased if a MP MRI scan was done first. And unnecessary biopsies would be reduced.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed
) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.